Key result
Integrating quality of life and survival measures in trial reporting allows for exploring the robustness of treatment recommendations based on patient tolerance of side-effects.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This statistical perspective highlights the need for clinical trials to integrate quality and length of life outcomes to better answer clinically relevant questions about patient trade-offs.
The reporting of trials has been dominated by a concentration on single measures of response, such as survival or extent of side-effects, perhaps selected as giving an impressive P value for treatment comparisons. Relevant questions about trade-offs are seldom answered or even envisaged in the trial design. Cardiovascular trials should provide evidence on quality of life after myocardial infarction or during antihypertensive therapy. Examples from oncology are used to illustrate how the robustness of treatment recommendation can be explored through a grid of quality adjustments, ranging from complete intolerance of side-effects to absolute acceptance of them. Treatment recommendations may need to be specific to patients unless they are independent of the system of quality adjustment used.
No takes yet. Share an insight, caveat, or question.
S M Gore (1988) reported a review. Integrating quality of life and survival measures in trial reporting allows for exploring the robustness of treatment recommendations based on patient tolerance of side-effects.
Synapse has enriched 10 related papers. Consider them for comparative context: